Pacira BioSciences (PCRX) News Today $24.88 -0.09 (-0.36%) Closing price 04:00 PM EasternExtended Trading$24.88 0.00 (0.00%) As of 05:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period U.S. Pharma Turns to China for Drug DealsApril 15 at 4:59 PM | uk.finance.yahoo.comIs Pacira BioSciences, Inc. (PCRX) the Best Pharma Stock to Buy for Long Term Growth?April 15 at 3:16 PM | insidermonkey.comPacira BioSciences, Inc. (NASDAQ:PCRX) Shares Acquired by Renaissance Technologies LLCRenaissance Technologies LLC boosted its position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 0.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,992,601 shares of the cApril 14 at 5:13 AM | marketbeat.comNorges Bank Takes Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)Norges Bank purchased a new stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 127,655 shares of the company's stock, valued at approximately $2,405,000. Norges Bank owned about 0.2April 14 at 3:31 AM | marketbeat.comPacira BioSciences, Inc. (NASDAQ:PCRX) Holdings Lifted by Wellington Management Group LLPWellington Management Group LLP boosted its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 3.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 470,191 shares of the company'sApril 12 at 4:24 AM | marketbeat.comVanguard Group Inc. Decreases Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)Vanguard Group Inc. cut its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 0.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,263,919 shares of the company's stock afteApril 12 at 3:37 AM | marketbeat.comPacira BioSciences (NASDAQ:PCRX) Shares Down 12.6% - Should You Sell?Pacira BioSciences (NASDAQ:PCRX) Shares Down 12.6% - Here's What HappenedApril 11, 2025 | marketbeat.comPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 11, 2025 | globenewswire.comThe Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers SquibbApril 10, 2025 | finance.yahoo.comPacira BioSciences (NASDAQ:PCRX) Shares Gap Up Following Analyst UpgradePacira BioSciences (NASDAQ:PCRX) Shares Gap Up Following Analyst UpgradeApril 10, 2025 | marketbeat.comPacira BioSciences (NASDAQ:PCRX) Earns "Buy" Rating from Needham & Company LLCNeedham & Company LLC restated a "buy" rating and issued a $32.00 target price on shares of Pacira BioSciences in a research note on Tuesday.April 10, 2025 | marketbeat.comPacira BioSciences (NASDAQ:PCRX) Price Target Raised to $65.00HC Wainwright boosted their target price on Pacira BioSciences from $48.00 to $65.00 and gave the company a "buy" rating in a research report on Tuesday.April 10, 2025 | marketbeat.comPacira BioSciences Remains A 'Buy' For Pain Management With The NOPAIN ActApril 10, 2025 | seekingalpha.comPacira BioSciences, Inc. (NASDAQ:PCRX) Shares Purchased by American Century Companies Inc.American Century Companies Inc. raised its position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 46.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 135,592 shares of theApril 9, 2025 | marketbeat.comPacira BioSciences (NASDAQ:PCRX) Shares Gap Up After Analyst UpgradeApril 9, 2025 | americanbankingnews.comPacira Biosciences Stock Rises On Patent Litigation Settlement: Retail Sentiment SoarsApril 8, 2025 | msn.comPCRX Stock Soars on Exparel Patent Settlement With Generic PlayersApril 8, 2025 | msn.comPacira BioSciences Shares Rise 15% on Patent Settlement Over ExparelApril 8, 2025 | marketwatch.comExodusPoint Capital Management LP Grows Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)ExodusPoint Capital Management LP raised its position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 232.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 212,824 shares of the company's stock aApril 8, 2025 | marketbeat.comTrexquant Investment LP Has $3.73 Million Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)Trexquant Investment LP reduced its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 61.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 198,090 sharesApril 8, 2025 | marketbeat.comPacira announces settlement of U.S. patent litigation for ExparelApril 7, 2025 | markets.businessinsider.comPacira BioSciences stock surges on patent litigation settlementApril 7, 2025 | investing.comPacira surges on patent settlement with FreseniusApril 7, 2025 | msn.comPacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPARELApril 7, 2025 | globenewswire.comIntegrated Quantitative Investments LLC Makes New $738,000 Investment in Pacira BioSciences, Inc. (NASDAQ:PCRX)Integrated Quantitative Investments LLC bought a new stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 39,147 shares of the company's stock, valueApril 7, 2025 | marketbeat.comArrowstreet Capital Limited Partnership Sells 505,307 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)Arrowstreet Capital Limited Partnership reduced its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 43.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 647,318 shares of the company's sApril 7, 2025 | marketbeat.comBrokerages Set Pacira BioSciences, Inc. (NASDAQ:PCRX) Price Target at $27.22April 7, 2025 | americanbankingnews.comPacira BioSciences, Inc. (NASDAQ:PCRX) Given Consensus Recommendation of "Hold" by BrokeragesPacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) has received a consensus recommendation of "Hold" from the nine brokerages that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have issued a hold raApril 6, 2025 | marketbeat.comKLP Kapitalforvaltning AS Makes New $447,000 Investment in Pacira BioSciences, Inc. (NASDAQ:PCRX)KLP Kapitalforvaltning AS bought a new stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 23,700 shares of the company's stock, valuedApril 6, 2025 | marketbeat.comPacira announces first patient dosed in Phase 2 ASCEND study of PCRX-201April 4, 2025 | markets.businessinsider.comPacira BioSciences Announces First Patient Dosed in Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the KneeApril 3, 2025 | globenewswire.comPrudential Financial Inc. Reduces Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)Prudential Financial Inc. reduced its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 42.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 254,168 shares of the company's stoApril 2, 2025 | marketbeat.comPacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare ConferenceApril 1, 2025 | globenewswire.comEasterly Investment Partners LLC Cuts Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)Easterly Investment Partners LLC cut its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 21.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 105,651 shares of the company's stock after selling 28,833 sMarch 28, 2025 | marketbeat.comSimplify Asset Management Inc. Buys Shares of 37,742 Pacira BioSciences, Inc. (NASDAQ:PCRX)Simplify Asset Management Inc. bought a new position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 37,742 shares of the company's stock, valued at approxMarch 24, 2025 | marketbeat.comWhat is Zacks Research's Estimate for PCRX FY2027 Earnings?Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) - Investment analysts at Zacks Research issued their FY2027 earnings per share estimates for Pacira BioSciences in a report issued on Thursday, March 20th. Zacks Research analyst R. Department forecasts that the company will earn $2.45 per sharMarch 24, 2025 | marketbeat.comPacira BioSciences, Inc. (NASDAQ:PCRX) Shares Acquired by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. grew its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 16.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 502,204 shares of the compaMarch 23, 2025 | marketbeat.comPacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by Connor Clark & Lunn Investment Management Ltd.Connor Clark & Lunn Investment Management Ltd. lessened its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 45.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 44,137 shareMarch 22, 2025 | marketbeat.comCommit To Buy Pacira BioSciences At $20, Earn 14.4% Annualized Using OptionsMarch 21, 2025 | nasdaq.comAmundi Purchases 15,431 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)Amundi increased its position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 200.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 23,114 shares of the company's stock after acquiring an additional 15,431 shaMarch 21, 2025 | marketbeat.comVictory Capital Management Inc. Sells 27,478 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)Victory Capital Management Inc. decreased its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 22.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 94,750 shares of the company's stock after selling 27March 18, 2025 | marketbeat.comPacira BioSciences adopts majority vote standard for director electionsMarch 16, 2025 | investing.comGreat Lakes Advisors LLC Sells 233,540 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)Great Lakes Advisors LLC decreased its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 49.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 236,552 shares of the company's stock after sMarch 16, 2025 | marketbeat.comWealthfront Advisers LLC Invests $1 Million in Pacira BioSciences, Inc. (NASDAQ:PCRX)Wealthfront Advisers LLC acquired a new stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 48,568 shares of the company's stock, valued at aMarch 16, 2025 | marketbeat.comBank of New York Mellon Corp Has $7.47 Million Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)Bank of New York Mellon Corp lifted its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 11.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 396,399 shares of the company's stocMarch 16, 2025 | marketbeat.comPacira BioSciences: Back On An Uptrend After Positive DevelopmentsMarch 14, 2025 | seekingalpha.comPacira BioSciences Confirms Receipt of Director Nominations from DOMA PerpetualMarch 14, 2025 | globenewswire.comPacira BioSciences (NASDAQ:PCRX) Trading 4.3% Higher - What's Next?Pacira BioSciences (NASDAQ:PCRX) Trading 4.3% Higher - Time to Buy?March 14, 2025 | marketbeat.comDOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciencesMarch 14, 2025 | prnewswire.comPCRX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 14 Deadline in Securities Class Action – PCRXMarch 13, 2025 | globenewswire.com Remove Ads Get Pacira BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address PCRX Media Mentions By Week PCRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PCRX News Sentiment▼0.820.80▲Average Medical News Sentiment PCRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PCRX Articles This Week▼169▲PCRX Articles Average Week Remove Ads Get Pacira BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Perrigo News Today Supernus Pharmaceuticals News Today Omeros News Today Nektar Therapeutics News Today Assembly Biosciences News Today Cumberland Pharmaceuticals News Today Eli Lilly and Company News Today Johnson & Johnson News Today AbbVie News Today Merck & Co., Inc. News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PCRX) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacira BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pacira BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PCRX Stock Free PCRX Stock Alerts